Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The product of RIPK3 is a member of the receptor-interacting protein (RIP) family of serine/threonine protein kinases, and contains a C-terminal domain unique from other RIP family members. Additionally we are shipping RIPK3 Antibodies (144) and RIPK3 Proteins (14) and many more products for this protein.
Showing 3 out of 14 products:
Human RIPK3 ELISA Kit for Sandwich ELISA - ABIN849440
Qing, Conegliano, Shashaty, Seo, Reilly, Worthen, Huh, Meyer, Mangalmurti: Red blood cells induce necroptosis of lung endothelial cells and increase susceptibility to lung inflammation. in American journal of respiratory and critical care medicine 2014
CHIP is a bona fide negative regulator of the RIPK1 (show RIPK1 ELISA Kits)-RIPK3 necrosome formation leading to desensitization of TNF (show TNF ELISA Kits)-mediated necroptosis
CNOT3 (show CNOT3 ELISA Kits) suppression promotes necroptosis by stabilizing mRNAs for cell death-inducing proteins, Ripk1 (show RIPK1 ELISA Kits) and Ripk3.
RIPK3 expression may allow unmasking the necroptotic signalling machinery in melanoma and points to reactivation of this pathway as a treatment option for metastatic melanoma.
Additionally, later in infection, RIP3 is cleaved by the coxsackievirus B3-encoded cysteine protease (show CTSB ELISA Kits) 3C(pro), which serves to abrogate RIP3-mediated necrotic signaling and induce a nonnecrotic form of cell death.
Results identify a crucial role for RIPK3-PGAM5-Drp1/NFAT signalling in NKT cell activation, and further suggest that RIPK3-PGAM5 signalling may mediate crosstalk between mitochondrial function and immune signalling.
although JNK (show MAPK8 ELISA Kits) activation and RIP3 expression are induced by FS, neither contributes to the liver injury.
The RIP3 expression is reduced in tumors compared to normal tissue in 85% of breast cancer patients, suggesting that RIP3 deficiency is positively selected during tumor growth/development.
Data implicate the infiltrating macrophages as a source of damaging inflammasomes after photoreceptor detachment in a RIP3-dependent manner and suggest a novel therapeutic target for treatment of retinal diseases.
PolyIC stimulation of cervical cancer cells induced necroptotic cell death, which was strictly dependent on the expression of the receptor-interacting protein (show RIPK1 ELISA Kits) kinase (show CDK7 ELISA Kits) RIPK3.
Data suggest that neoalbaconol-induced necroptosis include receptor interacting serine/threonine kinase (show TLK2 ELISA Kits) 1-dependent expression of tumor necrosis factor alpha (show TNF ELISA Kits) and receptor interacting serine/threonine kinase 3-dependent generation of reactive oxygen species.
we demonstrate that the phosphorylation of Ser345 is not required for the interaction between RIPK3 and MLKL in the necrosome, but is essential for MLKL translocation, accumulation in the plasma membrane, and consequent necroptosis.
Data indicate that receptor-interacting serine-threonine kinase 3 (RIPK3) deletion prevents inflammatory phenotypes in CreLysM (lysozyme (show LYZ ELISA Kits) M) Casp8fl/fl (caspase 8 (show CASP8 ELISA Kits)) mice.
RIP3 (show MPRIP ELISA Kits)-induced activation of CaMKII (show CAMK2G ELISA Kits), via phosphorylation or oxidation or both, triggers opening of the mitochondrial permeability transition pore and myocardial necroptosis.
RIPK3 is an essential molecule to maintain the temporal manner of the normal progression of wound closure
deficiency of RIPK3 or MLKL prevents oxalate crystal-induced acute kidney injury.
although JNK (show MAPK8 ELISA Kits) activation and RIP3 (show MPRIP ELISA Kits) expression are induced by FS, neither contributes to the liver injury.
RIPK3 can promote NLRP3 inflammasome and IL-1beta inflammatory responses independent of MLKL and necroptotic cell death
Data implicate the infiltrating macrophages as a source of damaging inflammasomes after photoreceptor detachment in a RIP3 (show MPRIP ELISA Kits)-dependent manner and suggest a novel therapeutic target for treatment of retinal diseases.
The product of this gene is a member of the receptor-interacting protein (RIP) family of serine/threonine protein kinases, and contains a C-terminal domain unique from other RIP family members. The encoded protein is predominantly localized to the cytoplasm, and can undergo nucleocytoplasmic shuttling dependent on novel nuclear localization and export signals. It is a component of the tumor necrosis factor (TNF) receptor-I signaling complex, and can induce apoptosis and weakly activate the NF-kappaB transcription factor.
receptor-interacting serine-threonine kinase 3
, receptor-interacting serine/threonine-protein kinase 3-like
, RIP-like protein kinase 3
, receptor interacting protein 3
, receptor-interacting protein 3
, receptor-interacting serine/threonine-protein kinase 3
, homocysteine respondent protein HCYP2